Pulmonary Arterial Hypertension study: LIQ861
Official title A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
ClinicalTrials.gov ID: NCT07759804
What this study is testing
What is LIQ861 (treprostinil) inhalation powder?
This is an investigational inhaled powder medicine being studied for pulmonary arterial hypertension. It is designed to relax the blood vessels in the lungs to help lower blood pressure in that area.
Also referred to as treprostinil.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study checks how safe and tolerable inhaled treprostinil is when people stop selexipag and start the inhaler. It also looks at changes in walking distance, a heart‑strain blood marker, and symptoms.
- Who it's for
- Adults with pulmonary arterial hypertension who are currently taking selexipag.
- What's involved
- Participants will stop selexipag on day one and start inhaling treprostinil four times a day with a handheld dry‑powder inhaler. The dose may be increased over time based on tolerance. All participants receive the inhaler and will have tests and questionnaires during the study.
- Time commitment
- The study lasts 16 weeks, with regular visits for dosing, monitoring, and assessments.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Male or female 18 to 80 years of age
- Documented findings on right heart catheterization consistent with a diagnosis of WHO Group 1 pulmonary arterial hypertension of one of the following...
- Receiving selexipag at any dose between 200 and 1600 mcg twice daily for at least 90 days, and willing and able to transition from selexipag to...
- May be receiving up to 2 additional approved non-prostacyclin oral PAH therapies at a stable dose and regimen, planned to continue unchanged for the...
- New York Heart Association Functional Class II or III
You likely can't join if
- Pulmonary hypertension in WHO Group 2, 3, 4, or 5, or a WHO Group 1 subtype not listed in the inclusion criteria
- Clinically significant left-sided heart disease by echocardiography, including left ventricular ejection fraction ≤ 45%, left atrial volume index \>...
- Symptomatic coronary artery disease within the previous 6 months
- Prior atrial septostomy
See the full eligibility criteria
- Male or female 18 to 80 years of age
- Documented findings on right heart catheterization consistent with a diagnosis of WHO Group 1 pulmonary arterial hypertension of one of the following subtypes: idiopathic PAH; heritable PAH; drug- or toxin-induced PAH
- Receiving selexipag at any dose between 200 and 1600 mcg twice daily for at least 90 days, and willing and able to transition from selexipag to LIQ861 due to unsatisfactory clinical response or side effects issues
- May be receiving up to 2 additional approved non-prostacyclin oral PAH therapies at a stable dose and regimen, planned to continue unchanged for the duration of the study
- New York Heart Association Functional Class II or III
- Able to demonstrate correct use of the dry powder inhaler
- Pulmonary hypertension in WHO Group 2, 3, 4, or 5, or a WHO Group 1 subtype not listed in the inclusion criteria
- Clinically significant left-sided heart disease by echocardiography, including left ventricular ejection fraction ≤ 45%, left atrial volume index \> 48 mL/m², or hemodynamically significant valvular disease
- Symptomatic coronary artery disease within the previous 6 months
- Prior atrial septostomy
The study team makes the final eligibility decision.
Where it is enrolling
- Columbus, Georgia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Columbus, Georgia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.